ABUS—You’re preaching to the choir insofar as I’m not impressed by the AB-729 data either. (Did you notice the word, “not” in the second sentence of the second paragraph of #msg-155712858?)
At best, AB-729 has a flat dose response; at worst, AB-729 may not have any dose that provides both efficacy and safety (unless the 90mg dose, which has yet to be reported, threads the needle). Moreover (as previously posted), I’m not convinced that targeting HBsAg is the right way to seek a functional cure in HBV.
p.s. ABUS is +25% today as I’m typing (vs +51% in yesterday’s AH session). Cooler heads at work today.
News 
Market Data 
Discover 
